Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Fizazi says PROTEASE was positive for metastasis-free survival only after investigators amended the protocol to include PSMA PET; the original conventional-imaging endpoint had a p-value above 0.05. That split interpretation—positive by amended endpoint, not by original—fuels debate about whether to intensify high-risk localized disease. He notes opinions remain divided among clinicians.

Related Insights

When PSMA PET became the standard of care for detecting prostate cancer metastasis, the PROTEUS trial amended its protocol to include it alongside conventional imaging. The trial's positive Metastasis-Free Survival (MFS) result was driven by this composite endpoint, as the analysis using conventional imaging alone was not statistically significant.

PROTEUS changed its primary endpoint mid-study to include PSMA PET-detected metastasis. While this led to a statistically positive result, it raises concerns that the benefit is merely earlier detection (lead-time bias) rather than a true improvement in curing micrometastatic disease and improving overall survival.

While many clinical trials haven't officially counted PSMA-PET only disease as metastatic, clinicians have latitude. If a PSMA-PET scan reveals aggressive, multifocal disease, especially with a rapidly rising PSA, it should be treated as incurable metastatic cancer, justifying the initiation of systemic therapy.

For on-treatment monitoring, a fixed absolute tumor volume increase (e.g., 50mL) on PSMA-PET is a superior marker of progression than a percentage-based change. Percentage metrics unfairly disadvantage patients with high-volume baseline disease, where a small relative change can represent massive, clinically significant growth.

While PSMA PET scans are more sensitive, they create a clinical dilemma because pivotal trials defining treatment efficacy were based on conventional imaging (CT/bone scans). This forces oncologists to either re-image patients with older technology to match trial criteria or make treatment decisions based on PET data that lacks a clear evidence-based framework for response assessment.

When looking only at the original endpoint of metastasis-free survival by conventional imaging, the PROTEUS trial was not positive. This result is consistent with the negative ENZERAD trial, which tested a similar drug combination with radiation instead of surgery. This cross-trial consistency suggests adding an ARPI may not provide a substantial benefit in this setting.

Fizazi criticizes PROTEASE's control arm because it was not surgery alone; both arms received neoadjuvant ADT, which drives postoperative PSA to zero. That prevents clinicians from using PSA to trigger adjuvant radiation or intensification, a key limitation for translating the trial into practice. He calls this a design criticism.

Despite meeting its primary endpoint, the PROTEUS trial provides no validated biomarkers to identify which patients actually benefit from the intensified therapy. This lack of a predictive signature means applying the results in the clinic amounts to uniform escalation, likely overtreating many patients for an uncertain benefit, making it difficult to implement.

The introduction of highly sensitive PSMA PET scans means established endpoints like Metastasis-Free Survival (MFS) may no longer be valid. A metastasis detected by PET likely has a different, better prognosis than one found with older imaging, requiring new validation for this key endpoint.

Though EMBARK trial patients were negative on conventional imaging, an analysis suggests over 80% had PSMA PET-detectable disease. This reframes the landmark study, suggesting its findings may apply more to treating low-volume metastatic disease intermittently rather than purely biochemical recurrence.